GlobeNewswire by notified

ObsEva Announces Third Quarter 2021 Financial Results and Business Update

Share


-Linzagolix for uterine fibroids: Pending regulatory approval in the US and Europe with commercial planning efforts underway-

-Linzagolix for endometriosis: Readout from Phase 3 EDELWEISS 3 study expected in Q4:21-

-Ebopiprant: Global License Agreement completed with Organon-

-Actively pursuing new indications and partnerships to maximize value of pipeline candidates-


Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

GENEVA, SwitzerlandNovember 4, 2021 – ObsEva SA (NASDAQ: OBSV)(SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported financial results for the quarter ended September 30, 2021 and provided a business update.

“Recent months have been noteworthy for many reasons, especially the progress made in defining the futures of both the linzagolix and ebopiprant programs,” reported Brian O’Callaghan, CEO of ObsEva. “Regulatory filings for approval of linzagolix in the treatment of uterine fibroids have now been made in both Europe and the US. As a result, commercialization planning is now underway, via our recently announced relationship with Syneos Health to commercialize linzagolix. The future path of ebopiprant was also established with our license agreement with Organon to develop and commercialize ebopiprant. We are looking forward to seeing the advancement of this investigational agent to potentially benefit many patients in the future. As I reflect on my first year with the company, I am incredibly proud of our numerous achievements across all areas of the business, and I am increasingly confident in the team’s ability to continue to grow and redefine ObsEva’s future.”


Anticipated Milestones

ObsEva expects to achieve the following key clinical and regulatory objectives in 2021:

  • Linzagolix for uterine fibroids: Committee for Medicinal Products for Human Use (CHMP) marketing approval recommendation (Q4:21)
  • Linzagolix for endometriosis: Phase 3 EDELWEISS 3 study topline results readout (Q4:21)


Pipeline Update

  • Linzagolix for Uterine Fibroids:  ObsEva is developing linzagolix, an oral GnRH receptor antagonist with the prospect to treat more women due to its potential best-in-class efficacy, a favorable tolerability profile and unique, and flexible dosing options for the treatment of uterine fibroids. If approved, linzagolix will be the only GnRH antagonist in uterine fibroids with a low dose non-ABT option to address the needs of women who cannot or do not want to take hormones. The Company is working closely with the European Medicines Agency (EMA) to achieve marketing approval, with an approval recommendation (positive opinion) from the CHMP projected in Q4:2021. In Q3:2021, the Company also submitted a New Drug Application with the US FDA. Commercial planning efforts are also underway with a recently established relationship with Syneos Health (NASDAQ: SYNH).

  • Linzagolix for Endometriosis: The EDELWEISS 3 study in the EU is progressing as planned, with randomization of patients completed and primary endpoint data expected in Q4:2021. The ongoing Phase 3 EDELWEISS 3 study (Europe and US) enrolled 486 patients with endometriosis-associated pain, with a co-primary endpoint of response on both dysmenorrhea (menstrual pain) and non-menstrual pelvic pain. The study includes a 75 mg once-daily dose without hormonal ABT, and a 200 mg once-daily dose in combination with hormonal ABT (1 mg E2 / 0.5mg NETA). Subjects who complete the initial six-month treatment period have the option to enter a six-month treatment extension


  • Ebopiprant for Treatment of Preterm Labor:  In Q3:2021, ObsEva granted a license to Organon (NYSE: OGN) for the global development, manufacturing and commercial rights to ebopiprant. Plans for the further development of ebopiprant are yet to be announced.


  • Nolasiban for In Vitro Fertilization:  ObsEva is also advancing nolasiban, an oral oxytocin receptor antagonist, to improve live birth rates in women undergoing in vitro fertilization.


Financial Update

Net income for the quarter ended September 30, 2021 was $0.8 million, or $0.01 per share, compared with a net loss of $24.4 million, or $0.49 per share, for the quarter ended September 30, 2020. Research and development expenses were $11.5 million and general and administrative expenses were $7.0 million for the quarter ended September 30, 2021, compared with $20.1 million and $3.5 million, respectively, for the corresponding prior year quarter. Net income for the quarter ended September 30, 2021 included non-cash expenses of $1.7 million for stock-based compensation, compared with $1.9 million for stock-based compensation in the corresponding prior year quarter.

As of September 30, 2021, ObsEva had cash and cash equivalents of $62.9 million, compared with $31.2 million as of December 31, 2020.

In October 2021, ObsEva entered into a convertible note financing agreement with certain funds and accounts managed by JGB Management, Inc., which is structured to provide up to $135 million in borrowing capacity, available in nine tranches, subject to certain conditions to funding.

The third quarter 2021 financial report will be available in the financial reports section of the Company’s website.


To access the financial reports section of the Company’s website, please click [here].

To access the third quarter 2021 financial report directly, please click [here].


About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com

Cautionary Note Regarding Forward Looking Statements of ObsEva SA
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of and commercialization plans for ObsEva’s product candidates, expectations regarding regulatory and development milestones, including the potential timing of regulatory submissions to the EMA and FDA and ObsEva’s ability to obtain and maintain regulatory approvals for its product candidates, and the results of interactions with regulatory authorities. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, ObsEva’s reliance on third parties over which it may not always have full control, and the capabilities of such third parties; the impact of the ongoing novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2020 filed with Securities and Exchange Commission (SEC) on March 5, 2021 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.


For further information, please contact:

CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact:
Joyce Allaire
jallaire@lifesciadvisors.com
+1 (617) 435-6602

Consolidated Statements of Comprehensive Loss

Three-Month Period
Ended September 30,
Nine-Month Period
Ended September 30,
(In USD ’000, except share and per share data) - unaudited2021202020212020
Operating income other than revenue20,098320,10811
OPERATING EXPENSES
Research and development expenses(11,531)(20,125)(41,532)(52,690)
General and administrative expenses(7,035)(3,514)(15,114)(9,414)
Total operating expenses(18,566)(23,639)(56,646)(62,104)
OPERATING INCOME / (LOSS)1,532(23,636)(36,538)(62,093)
Finance income128184702292
Finance expense(822)(918)(2,423)(2,619)
NET INCOME / (LOSS) BEFORE TAX838(24,370)(38,259)(64,420)
Income tax (expense) / benefit(19)(14)(70)5
NET INCOME / (LOSS) FOR THE PERIOD819(24,384)(38,329)(64,415)
Net earnings / (loss) per share
Basic0.01(0.49)(0.53)(1.35)
Diluted0.01(0.49)(0.53)(1.35)
Weighted Average Number of Shares Outstanding77,971,00850,086,92374,152,70547,848,862

Consolidated Balance Sheets

(In USD ’000) - unauditedSeptember 30,
2021
December 31,
2020
ASSETS
Current assets
Cash and cash equivalents62,88431,183
Other receivables3,428397
Prepaid expenses5,7465,388
Total current assets 72,058 36,968
Non-current assets
Right-of-use assets7301,425
Furniture, fixtures and equipment62151
Intangible assets24,50326,608
Other long-term assets283295
Total non-current assets 25,578 28,479
Total assets 97,636 65,447
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities
Other payables and current liabilities7,34710,760
Accrued expenses10,72310,248
Current lease liabilities698696
Total current liabilities 18,768 21,704
Non-current liabilities
Non-current lease liabilities383952
Non-current borrowings25,62325,300
Post-employment obligations8,1168,218
Other long-term liabilities577919
Total non-current liabilities 34,699 35,389
Shareholders’ equity
Share capital6,9484,878
Treasury shares(630)(304)
Share premium424,561356,822
Reserves31,01426,353
Accumulated losses(417,724)(379,395)
Total shareholders’ equity 44,169 8,354
Total liabilities and shareholders’ equity 97,636 65,447

###

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Connecterra and Lely Announce Strategic Partnership2.12.2021 15:05:00 CET | Press release

Following the completion of a successful pilot, the two companies will deepen their collaboration and commercial relationship Amsterdam, The Netherlands, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Today Dutch-based startup, Connecterra, a world leader in using artificial intelligence to deliver insights to farmers, and Lely, the global leading supplier of robotics and management systems for dairy farming, announced the start of a robust co-development and commercial partnership. The announcement follows a pilot with Lely’s Digital Farming Group. The pilot program was designed to test an integration between Lely Horizon and Connecterra’s artificial intelligence platform, Ida. The successful effort has resulted in commitments to several strategic initiatives. As a first step in the agreement, Lely will now license Ida Enterprise for use in their farm management system Lely Horizon. “We believe that digitization of dairy farming is key and needs to be handled with care. Integrating with partners l

Fobi Announces Signing Of Amazon Fulfillment And Business Seller Agreement2.12.2021 13:45:00 CET | Press release

Fobi’s hardware and software solutions will now be available on Amazon Business, reaching over five million businesses worldwide VANCOUVER, British Columbia, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Fobi AI Inc. Inc.(FOBI:TSXV FOBIF:OTCQB) (the “Company” or “Fobi”), a leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement, announced it has signed an agreement with Amazon for distribution and fulfillment of Fobi AI’s various hardware products. As part of the agreement, Fobi will also become an Amazon Business Seller which will enable Fobi to gain access to Amazon’s global e-commerce, logistics and fulfillment infrastructure. By joining Amazon Business, Fobi immediately reaches over 5 million business customers in nine countries: a network that Fobi is very proud to now be included in. Fobi will now generate additional revenue through hardware, products and services sold on Amazon Business. Fobi will be launching their Fobi 3.0 I

Mandalay Resources Corporation Completes Sale of Cerro Bayo Mine to Equus Mining2.12.2021 13:30:00 CET | Press release

TORONTO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND, OTCQB: MNDJF) is pleased to announce that it has completed the previously announced sale of its Cerro Bayo mine in Region XI, Southern Chile (see Mandalay press releases dated October 12, 2021, and October 8, 2019). Pursuant to the transaction, Equus Mining Limited (“Equus”) acquired the Cerro Bayo mine, including its mining properties, resources and mine infrastructure as well as a 1,500 tonnes per day processing plant, in exchange for 587,502,438 ordinary shares in the capital of Equus. Mandalay also retains a 2.25% net smelter royalty on production from the Cerro Bayo mining claims once the mine has produced at least 50,000 ounces of gold equivalent, subject to a re-purchase option in favour of Equus, and remains responsible for 50% of approved site closure costs at Cerro Bayo. In addition, Equus will appoint Ryan Austerberry, Mandalay’s Costerfield mine General Manager

CTG and Micro Focus Extend European Platinum Partnership to French Market2.12.2021 12:55:00 CET | Press release

PARIS, Dec. 02, 2021 (GLOBE NEWSWIRE) -- CTG (NASDAQ: CTG), a leading provider of digital IT services and solutions in North America and Western Europe, today announced an expanded strategic partnership agreement with Micro Focus to now include CTG France. The partnership aligns CTG’s testing capabilities with Micro Focus’ Application Lifecycle Management (ALM) software to help clients accelerate their software delivery and ensure quality and application performance at every stage of the digital application lifecycle. Leveraging the global organization’s decades of experience, a team of more than 500 testers, and a network of more than 3,000 crowdtesters, CTG France offers its clients comprehensive Application Testing Solutions. The Company’s Testing Solutions portfolio includes advisory consulting, test methodology and process, performance testing, manual functional testing, testing automation, test tool implementation, and crowdtesting. Many of CTG’s more than 400 clients use Micro F

WESTPAY AND EASYCASHIER COMPLETE SUCCESSFUL LAUNCH OF MULTI-USER PAYMENT SOLUTION2.12.2021 12:45:00 CET | Press release

Westpay AB, a leading fintech company, has enabled multi-user functionality (MultiTID) in their payment application. This solution makes it possible for several users to share a physical payment solution. This is in demand in several verticals, such as hairdressers, who share premises but run their business individually. EasyCashier, a leading POS provider and a close partner to Westpay will be the first partner that offer this solution for their customers. - Again, I am proud that Westpay continues to push the limits to what you can expect from a payment solution.We have seen this functionality before, but the way we manage to simplify the use of sharing payment solutions. It is also happy that EasyCashier embraces this solution and enables it for their customers. They are a solid, reliable partner with great expertise and experience, says Hans Edin, CCO at Westpay. - Quality and innovation are two vital features for us at EasyCashier. We always try to level up the value as well as th

TGS Share Repurchase2.12.2021 10:57:49 CET | Press release

Oslo, Norway (02 December 2021) – On period from 25 November 2021 to 01 December 2021, TGS ASA (TGS) purchased 67,328 own shares on the Oslo Stock Exchange at an average price of NOK 85.1890 per share. Following the purchase TGS owns 1,226,303 shares, representing 1.044% of the total outstanding shares. The shares were purchased in connection with the share repurchase announced on 11 February 2021. Overview of transactionsDateAggregated daily volume (number of shares)Weighted average share price per day (NOK)Total daily transaction value (NOK)25-Nov-2110,87888.9977968,11726-Nov-2120,00084.97931,699,58629-Nov-212,00084.2400168,48030-Nov-2120,00084.16361,683,2721-Dec-2114,45084.16241,216,147Previously disclosed buy-backs under the program (accumulated)1,143,975105.5774120,777,940Accumulated under the buy-back program1,211,303104.4442126,513,541The issuer's holding of own shares:Following the completion of the above transactions, TGS owns a total of 1,226,303 own shares, corresponding to

AB Linas Agro Group investors calendar for the 20222.12.2021 10:41:10 CET | Press release

A list of key information disclosure dates in 2022: February 28, 2022Interim half-year unaudited report for FY 2021/2022.March 1, 2022Investor Conference Webinar to introduce unaudited financial and activity results for the half-year of FY 2021/2022.May 31, 2022Interim unaudited report for 9 months of FY 2021/2022.June 1, 2022Investor Conference Webinar to introduce unaudited financial and activity results for 9 months of FY 2021/2022.August 31, 2022Interim unaudited report for 12 months of FY 2021/2022.September 2, 2022Investor Conference Webinar to introduce unaudited financial and activity results for 12 months of FY 2021/2022.Week 40 (Oct 3-7, 2022)Notice on Annual General Meeting of shareholders.Week 43 (Oct 24-28, 2022) Resolutions of the Annual General Meeting of shareholders and Annual audited results for FY 2021/2022.November 30, 2022Interim unaudited report for 3 months of 2022/2023 financial year.December 1, 2022Investor Conference Webinar to introduce unaudited financial an